Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dysport Injectable Product Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)

NCT03786770
View directory record Official record
Conditions
Frown Lines
Interventions
DaxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boca Raton, Florida • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines

NCT02718118
View directory record Official record
Conditions
Glabellar Lines, Wrinkles
Interventions
Dysport reconstituted at 1.5 mL (0.05 mL/injection), Dysport reconstituted at 2.5 mL (0.08 mL/injection)
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Greenwood Village, Colorado • Coral Gables, Florida • Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

NCT00660192
View directory record Official record
Conditions
Refractory Migraine
Interventions
Botox, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy

NCT03469999
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Dysport Injectable Product
Drug
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 22, 2026, 5:03 PM EDT
Not listed Phase 1Phase 2 Interventional

ASIS for Botox in Upper Limb Spasticity

NCT02074150
View directory record Official record
Conditions
Upper Limb Spasticity Unilaterally in Adults With History of Stroke, Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions
Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12,, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
Drug
Lead sponsor
li nguyen
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

NCT05330078
View directory record Official record
Conditions
Keloid
Interventions
Botulinum toxin type A, Vehicle
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Phase 4 Interventional

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

NCT07220382
View directory record Official record
Conditions
Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions
OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

NCT03825315
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
DAXI 80 U, DAXI 120 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Study of Botulinum Toxin and Recovery of Hand Function After Stroke

NCT01422161
View directory record Official record
Conditions
Stroke With Hemiparesis
Interventions
Botulinum Toxin commonly known as BOTOX®, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 22, 2026, 5:03 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

NCT05806164
View directory record Official record
Conditions
Urgency Urinary Incontinence
Interventions
Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox]
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain

NCT02173405
View directory record Official record
Conditions
Myofascial Pain Syndromes, Myofascial Trigger Point Pain, Trigger Point Pain, Myofascial
Interventions
OnabotulinumtoxinA, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Cleveland, Ohio • Mayfield Heights, Ohio • Westlake, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Antibiotic Usage Prior to OnabotulinumtoxinA Injection

NCT04754737
View directory record Official record
Conditions
Antibiotic Stewardship, Overactive Bladder, Onabotulinumtoxin A, UTI
Interventions
No antibiotic, Prophylactic antibiotic, cystoscopic injection of onabotulinumtoxinA
Other · Procedure
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

NCT03821402
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
26
States / cities
Downey, California • Fountain Valley, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Sling vs Botox for Mixed Incontinence

NCT04171531
View directory record Official record
Conditions
Urinary Incontinence, Stress, Urinary Incontinence, Urge
Interventions
Botox® injection, Mid-urethral sling
Drug · Device
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines

NCT02184988
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum purified neurotoxin, Type A
Biological
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

NCT04401176
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Heparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Exploring Advanced Imaging Techniques to Characterize Botulinum Toxin Diffusion in Human Muscle

NCT01412008
View directory record Official record
Conditions
Stroke, Muscle Spasticity
Interventions
Botox (botulinum toxin)
Drug
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 22, 2026, 5:03 PM EDT
Withdrawn Not applicable Interventional

Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in Spastic Esophageal Disorders

NCT02663206
View directory record Official record
Conditions
Esophageal Achalasia, Esophageal Spasm, Diffuse, Esophageal Motility Disorders
Interventions
peroral endoscopic myotomy, Botulinum toxin injection
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 22, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain

NCT02221648
View directory record Official record
Conditions
Lower Back Pain
Interventions
Placebo, AbobotulinumtoxinA Treatment
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

NCT02677805
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo, Botulinum Toxin A - Open Label
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Encinitas, California • Aventura, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder

NCT04020510
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

NCT04259086
View directory record Official record
Conditions
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Interventions
DaxibotulinumtoxinA for injection
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Manhattan Beach, California • San Diego, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Incobotulinumtoxin A and Yoga-like Isometric Exercise in Adolescent Idiopathic Lumbar Scoliosis

NCT04922983
View directory record Official record
Conditions
Scoliosis Idiopathic, Scoliosis; Adolescence, Scoliosis; Lumbar Region
Interventions
Botulinum toxin type A, Isometric Yoga-like exercise, Placebo
Drug · Behavioral
Lead sponsor
Manhattan Physical Medicine and Rehabilitation, LLP
Other
Eligibility
14 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Upper Limb Spasticity Extension Study

NCT01313312
View directory record Official record
Conditions
Nervous System Disorders
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 22, 2026, 5:03 PM EDT